Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspergillosis vaccine candidate
- Development stage
- Preclinical
- Lead developer
- Molecular Express
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Aspergillosis vaccine candidate (also known as VesiVax Af3/9) is a liposomal subunit vaccine candidate being developed by Molecular Express for the prevention of invasive pulmonary aspergillosis. The vaccine utilizes the proprietary VesiVax® liposomal antigen and adjuvant delivery platform to present two recombinant Aspergillus fumigatus surface antigens, Asp f 3 (peroxiredoxin) and Asp f 9 (extracellular cell wall glucanase Crf1). Formulated with adjuvants such as lipidated tucaresol, monophosphoryl lipid A (MPL), and PAM-3-CAG, the vaccine is designed to elicit robust CD4+ T-cell and humoral immune responses to protect immunocompromised individuals against Aspergillus infections, including azole-resistant strains.
- Other names
- VesiVax Aspergillosis vaccine
02
Targets
PRDX (Peroxiredoxin family)Aspergillus fumigatus antigen
Beyond the preview
Go deeper on aspergillosis vaccine candidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspergillosis vaccine candidate.